Recursion Pharmaceuticals, Inc. has reported a change in ownership, as detailed in a recent SEC filing. Fred Hassan is now listed as the reporting owner, which highlights active engagement in the company's management. This change is significant as it may influence the company's strategic direction and operations.

Background

Recursion Pharmaceuticals, Inc. operates within the biological products sector, specifically categorized under SIC 2836, which includes biological products excluding diagnostic substances. The company trades under the ticker RXRX on the Nasdaq exchange. It is classified as a large accelerated filer and has a fiscal year ending on December 31.

What the Filing Says

The filing, dated November 4, 2026, indicates that Fred Hassan is the reporting owner, with the change effective as of October 31, 2026. The filing states, "The undersigned hereby constitutes and appoints Nathan Hatfield, Kyle Nelson, and Jonathan Thomas as the undersigned’s true and lawful attorney-in-fact." This suggests that Hassan is taking steps to ensure proper management of his ownership interests.

Impact

This change in ownership may affect various stakeholders, including employees, investors, and competitors in the biological products industry. As leadership changes often lead to shifts in company strategy, Recursion Pharmaceuticals' direction may become more innovative or focused on different therapeutic areas, potentially impacting its market position.

What's Next

The filing does not say what happens next.